University of Oulu

Mobasheri A, Saarakkala S, Finnilä M et al. Recent advances in understanding the phenotypes of osteoarthritis [version 1; peer review: 2 approved]. F1000Research 2019, 8(F1000 Faculty Rev):2091 (https://doi.org/10.12688/f1000research.20575.1)

Recent advances in understanding the phenotypes of osteoarthritis

Saved in:
Author: Mobasheri, Ali1,2,3,4; Saarakkala, Simo2; Finnilä, Mikko2;
Organizations: 1Department of Regenerative Medicine, State Research Institute Centre for Innovative Medicine, Vilnius, 08661, Lithuania
2Research Unit of Medical Imaging, Physics and Technology, University of Oulu, Oulu, FI-90014, Finland
3Centre for Sport, Exercise and Osteoarthritis Research Versus Arthritis, Queen’s Medical Centre, Nottingham, UK
4ImmunoScience, Nordic Bioscience Biomarkers and Research, Herlev, DK-2730, Denmark
5Division of Internal Medicine & Dermatology, Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
6Rheumatology, Dijklander Hospital, 1620 AR Hoorn, The Netherlands
Format: article
Version: published version
Access: open
Online Access: PDF Full Text (PDF, 1.8 MB)
Persistent link: http://urn.fi/urn:nbn:fi-fe202003128099
Language: English
Published: F1000Research, 2019
Publish Date: 2020-03-12
Description:

Abstract

Recent research in the field of osteoarthritis (OA) has focused on understanding the underlying molecular and clinical phenotypes of the disease. This narrative review article focuses on recent advances in our understanding of the phenotypes of OA and proposes that the disease represents a diversity of clinical phenotypes that are underpinned by a number of molecular mechanisms, which may be shared by several phenotypes and targeted more specifically for therapeutic purposes. The clinical phenotypes of OA supposedly have different underlying etiologies and pathogenic pathways and they progress at different rates. Large OA population cohorts consist of a majority of patients whose disease progresses slowly and a minority of individuals whose disease may progress faster. The ability to identify the people with relatively rapidly progressing OA can transform clinical trials and enhance their efficiency. The identification, characterization, and classification of molecular phenotypes of rapidly progressing OA, which represent patients who may benefit most from intervention, could potentially serve as the basis for precision medicine for this disabling condition. Imaging and biochemical markers (biomarkers) are important diagnostic and research tools that can assist with this challenge.

see all

Series: F1000Research
ISSN: 2046-1402
ISSN-E: 2046-1402
ISSN-L: 2046-1402
Volume: 8
Article number: 2091
DOI: 10.12688/f1000research.20575.1
OADOI: https://oadoi.org/10.12688/f1000research.20575.1
Type of Publication: A2 Review article in a scientific journal
Field of Science: 3111 Biomedicine
Subjects:
Copyright information: © 2019 Mobasheri A et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  https://creativecommons.org/licenses/by/4.0/